Geoffrey Beran Rose Sells 5,779 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) insider Geoffrey Beran Rose sold 5,779 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total transaction of $41,204.27. Following the completion of the transaction, the insider now owns 285,278 shares in the company, valued at approximately $2,034,032.14. This represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Pulmonx Stock Up 0.5 %

LUNG traded up $0.04 during trading hours on Friday, hitting $7.48. 245,140 shares of the company's stock were exchanged, compared to its average volume of 335,956. Pulmonx Co. has a 12-month low of $5.46 and a 12-month high of $10.01. The firm has a 50 day moving average of $6.96 and a 200 day moving average of $6.94. The firm has a market cap of $297.67 million, a P/E ratio of -5.19 and a beta of 0.50. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The company had revenue of $23.77 million for the quarter, compared to the consensus estimate of $22.29 million. Analysts predict that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Pulmonx

A number of large investors have recently modified their holdings of the company. Mackenzie Financial Corp acquired a new position in shares of Pulmonx in the 4th quarter valued at $372,000. ProShare Advisors LLC acquired a new stake in shares of Pulmonx in the 4th quarter worth $72,000. Millennium Management LLC lifted its stake in shares of Pulmonx by 26.6% in the 4th quarter. Millennium Management LLC now owns 183,069 shares of the company's stock worth $1,243,000 after acquiring an additional 38,425 shares during the period. Graham Capital Management L.P. lifted its stake in shares of Pulmonx by 73.3% in the 4th quarter. Graham Capital Management L.P. now owns 18,071 shares of the company's stock worth $123,000 after acquiring an additional 7,641 shares during the period. Finally, D. E. Shaw & Co. Inc. lifted its stake in shares of Pulmonx by 8.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 392,836 shares of the company's stock worth $2,667,000 after acquiring an additional 32,049 shares during the period. 91.04% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Citigroup restated a "neutral" rating and issued a $7.50 price objective (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Wells Fargo & Company decreased their price objective on shares of Pulmonx from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $12.75.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.